High Impact Research
Emory Urology's clinical, basic, and translational research initiatives are an essential part of our mission to serve our patients. Discoveries achieved in the laboratory are easily translated to our clinical work, giving our patients quick access to new therapies and the opportunity to participate in unique clinical trials.
Our faculty scientists work to develop new treatments for both urological cancers — including prostate, bladder, kidney, and penile cancer — and such non-cancerous urologic problems as kidney stones, male infertility, urinary incontinence, urinary reconstruction, and erectile dysfunction. Our scientists receive funding from the NIH, other federal agencies, and foundation, corporate, and private sources, and regularly report the results of their studies in the peer reviewed literature.
Emory Urology fosters a collaborative team research environment and endorses cooperative efforts that involve our investigators partnering with researchers from other disciplines on projects that concentrate on areas of common interest.
Many of our faculty are also members of Winship Cancer Institute, the only National Cancer Institute-designated comprehensive cancer center in the state of Georgia, which has the capacity to offer clinical trials which provide patients with access to cutting-edge care that is often not available elsewhere.
In addition to Emory Urology trials, all clinical trials currently available at Emory can be viewed here.
Research Areas and Associated Clinical Trials
Urology Research Spotlights
- Enrolling for new upper tract urothelial cancer clinical trial
- Go Behind the Scenes of the Jindan Yu Lab
- AI Tools May Identify prostate cancer patient adjuvant therapy
- Dr. Haydn Kissick awarded $1.25M grant to immune response to cancer
- Study evaluates trends in fertility clinics (Akanksha Mehta)
- Dr. Akanksha Mehta on Recruitment and retention strategies for women in urology
- Researchers find AI can detect prostate cancer missed on MRI scans
- Dr. Jinan Yu shares her journey to becoming a prostate cancer research luminary
- Dr. Vikram Narayan on the evolving landscape of bladder cancer
- Dr. Vikram Narayan discusses FDA-approval for nadofaragene firadenovec